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Abstract
AIM: To determine which baseline factors of chronic 
hepatitis B patients are predictive of virological 
response to Peginterferon a-2b therapy.
METHODS: A total of 21 HBeAg-positive chronic 
hepatitis B (CHB) patients treated with Peginterferon 
a-2b were recruited. They were treated with 
Peginterferon a-2b (0.5-1.0 mg/kg per week) for 
24 wk and followed up for 24 wk. Clinical and 
laboratory data of the patients were determined at 
pretreatment and at week 12, at 24 during treatment, 
and at week 48 during follow up.
RESULTS: Ten patients achieved a virological response 
at the end of treatment. Their baseline serum alanine 
aminotransferase (ALT), thyroid-stimulating hormone 
(TSH), and total thyroxin (TT4) levels were significantly 
different from those who failed treatment. The positive 
predictive values (PPV) and negative predictive values 
(NPV) of ALT, TSH, and TT4 were 75% and 89 %, 75% 
and 89 %, and 75% and 75%, respectively. Moreover, 
combinations of the baseline ALT and TT4, ALT and 
TSH, TT4 and TSH levels had much higher PPV and 
NPV (86% and 88%, 89% and 100%, 83% and 100%, 
respectively).
CONCLUSION: Baseline serum ALT, TSH, and TT4 
levels, especially in combination, have high predictive 
values of virological response to Peginterferon a-2b in 
HBeAg-positive CHB patients.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a worldwide 
health problem. More than 400 million people are 
chronically infected with HBV and are at risk of  
developing liver cirrhosis and hepatocellular carcinoma. 
Each year more than one million people die from HBV-
related liver diseases[1-4].
At present, the two main categories of  antiviral 
drugs for chronic hepatitis B are interferon (including 
Peginterferon) and nucleoside/nucleotide analogs. 
Many studies have shown that an elevated serum 
ALT level is associated with virological response and 
HBeAg seroconversion in CHB patients[5-8]. Besides 
higher serum ALT level, some studies also showed that 
higher aspartate aminotransferase (AST) level, increased 
histological activity in biopsy specimens, female sex, 
and lower serum HBV DNA levels are associated with 
a higher probability of  HBeAg seroconversion in CHB 
patients treated with interferon-based therapies[9-13]. It 
is also reported that the HBV genotype is an important 
predictor of  response to interferon-based therapies[14-17].
Recently, serum HBeAg levels have been used as 
www.wjgnet.com
outcome predictors of  sustained virological response 
to Peginterferon a-2a in HBeAg-positive CHB patients 
and showed high negative predictive values (NPVs) at 
week 24 of  therapy[18]. Another study showed that early 
serum HBsAg drops also had high predictive values of  
sustained virological response to Peginterferon a-2a in 
HBeAg-negative chronic hepatitis B patients both at 
week 12 and 24[19].
However, the predictive values of  other factors, 
especially the baseline factors for virological response 
to Peginterferon a-2b therapy are not clear. Therefore, 
in this study, we aimed to determine how well the 
baseline factors predicted the virological response to 




The study was approved by the Investigation and Ethics 
Committee for Human Research at the Peking University 
First Hospital (Beijing, China). All patients provided 
informed written consent.
Patients and study design
Twenty-one consecutive HBeAg-positive chronic 
hepatitis B patients were evaluated. Patients were treated 
with Peginterferon a-2b at a dose of  0.5-1.0 mg/kg 
per week for 24 wk. Clinical and laboratory data of  the 
patients were determined before treatment, at week 
12, and 24 during treatment. Thereafter they were 
scheduled for follow-up visits every 12 wk. End of  
treatment (EOT) response was defined as more than 
2 log10 IU/mL reduction in HBV DNA levels at the EOT. 
Non-response was defined as less than 2 log10 IU/mL 
reduction in HBV DNA levels at the EOT.
Measurement of serologic markers of HBV
HBsAg, antibody to HBsAg, HBeAg, antibody to HBeAg 
and anti-HBc were measured using a microparticle 
enzyme immunoassay (Abbott Laboratories, North 
Chicago, IL). The HBV genotype was determined using 
the INNO LiPA HBV genotyping assay. Serum HBV 
DNA was measured using the TaqMan polymerase 
chain reaction assay [COBAS TaqMan, Roche Molecular 
System (lower limit of  detection, 20 IU/mL)]. 
Measurement of biochemical markers
Alanine aminotransferase (ALT) and aspar tate 
aminotransferase (AST) were measured using a Hitachi 
Model 7600 Series Automatic Analyzer (Hitachi). Thyroid-
stimulating hormone (TSH), total triiodothyronine 
(TT3), and total thyroxin (TT4) levels were measured 
using a Centaur Automated Chemiluminescence 
System (Bayer).
Statistical analysis
Quantitative variables were expressed as the median 
with interquartile ranges (IQR), and categorical variables 
as frequencies. Comparisons between groups of  
quantitative and qualitative variables were performed 
using the Mann-Whitney U test and the Fisher’s exact 
test, respectively. The accuracy of  serum factors to 
predict virological response was assessed using the 
receiver operating characteristic curve. The cutoff  
value was chosen according to the receiver operating 
characteristic curve when the sensitivity and specificity 
were both relatively high for the selective baseline factor. 
All tests were two-sided and used a significance level of  
0.05. Data handling and analysis were performed with 
SPSS software for windows, version 13.0 (SPSS Inc., 
Chicago, IL).
RESULTS
Baseline characteristics of patients
The baseline characteristics of  the 21 HBeAg-positive 
CHB patients are shown in Table 1. The median age 
was 25 years (range, 20-39), and 81% of  them were male 
(17/21). The median value of  serum HBV DNA levels 
was 8.2 log10 IU/mL (IQR, 7.5-8.7 log10 IU/mL). The 
distribution of  HBV genotype was: B, 24%; C, 76%. The 
median values of  serum ALT, AST, TSH, TT3, and TT4 
level were 147 IU/L (IQR, 123-201 IU/L), 65 IU/L 
(IQR, 51-97 IU/L), 2.06 mIU/L (IQR, 1.41-3.10 mIU/L), 
2.22 nmol/L (IQR, 2.04-3.03 nmol/L), and 111.4 nmol/L 
(IQR, 96.8-140.6 nmol/L) respectively. The baseline 
TT3 and TT4 values of  one patient were not assayed at 
pretreatment. Serological tests were negative for hepatitis 
C virus, hepatitis D virus, and human immunodeficiency 
virus in all patients.
Virological response
Of  the 21 patients, ten (48%) showed an EOT response, 
and eleven (52%) were non-responders. Four patients 
(19%) obtained HBeAg seroconversion at the end of  
treatment (week 24). However, two of  the four HBeAg 
seroconversion patients lost anti-Hbe, while another 
six patients achieved HBeAg seroconversion at week 
48. The median value of  serum HBV DNA levels were 
2.7 log10 IU/mL (IQR, 1.9-4.0 log10 IU/mL) and 3.1 
log10 IU/mL (IQR, 1.8-6.6 log10 IU/mL) in responders 
at week 24 and 48 respectively. In non-responders, 
The median value of  serum HBV DNA levels were 
7.4 log10 IU/mL (IQR, 6.8-7.9 log10 IU/mL) and 7.6 
log10 IU/mL (IQR, 7.1-8.7 log10 IU/mL) at week 24 
and 48 respectively. The baseline ALT and TT4 level 
were significantly higher in responders than in non-
responders(both P < 0.05, Table 1). However, the 
baseline TSH level was significantly lower in responders 
than in non-responders(P < 0.05, Table 1). The baseline 
age was similar between responders and non-responders.
Predictability
To determine how well the baseline ALT, TSH and TT4 
levels predicted virological response to Peginterferon a-2b 
therapy, we performed receiver operating characteristic 
curves for each parameter. The areas under the curves of  
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ALT, TSH, and TT4 were 0.827 (P = 0.011), 0.773 (P = 
0.035), and 0.778 (P = 0.037), respectively. Accordingly, 
we chose cutoff  values of  140 IU/L, 2.4 mIU/L, and 
120 nmol/L for ALT, TSH, and TT4, respectively. 
Correspondingly, their positive predictive values (PPV) 
and negative predictive values (NPV) were 75% and 89 %, 
75% and 89 %, and 75% and 75% (Table 2). We further 
performed the combination of  the baseline ALT and 
TT4, ALT and TSH, and TT4 and TSH to predict the 
virological response. We found that their PPV and NPV 
were 86% and 88%, 89% and 100%, and 83% and 100%, 
respectively (Table 2).
DISCUSSION
Nowadays, more and more doctors are taking the 
initiative in individualized treatment for chronic hepatitis 
B patients. With the purpose of  taking individualized 
treatment, it is important to evaluate the baseline status 
of  each patient at the start of  treatment and to then 
decide which antiviral drug is the best choice. For those 
patients who are not likely to benefit from Peginterferon 
a-2b therapy, an early switch to nucleoside/nucleotide 
analogs is essential.
Recently, a study showed that HBeAg levels had 
high negative predictive values (NPVs) at week 24 of  
sustained virological response to Peginterferon a-2a 
in HBeAg-positive CHB patients[18]. While in HBeAg-
negative CHB patients, early serum HBsAg drops also 
had high predictive values of  sustained virological 
response to Peginterferon a-2a at week 12 and 24[19].
In our study, 21 HBeAg-positive CHB patients were 
treated with Peginterferon a-2b for 24 wk and followed 
up for 24 wk. We found that baseline serum ALT, TSH, 
and TT4 levels, and especially the combination of  
these factors, had high predictive values of  virological 
response to Peginterferon a-2b therapy.
To identify the baseline predictors of  virological 
response, we performed univariate analysis and receiver 
operating characteristic curves for baseline serum ALT, 
TSH, and TT4 levels, and found that the cutoff  value of  
140 IU/L of  baseline serum ALT level had a relatively 
high predictive value of  virological response. The 
cutoff  values for TSH and TT4 were 2.4 (mIU/L) and 
120 (nmoI/L), respectively. Moreover, we found that 
combinations of  these factors could further improve the 
PPV and NPV scores.
Some studies have shown that the rates of  HBeAg 
loss and seroconversion were correlated with the baseline 
level of  ALT. In patients with a higher baseline level 
of  ALT, the rates of  HBeAg loss and seroconversion 
during lamivudine therapy were also significantly higher 
at the end of  year three[7]. A previous study showed that 
CHB patients with normal ALT levels respond very 
poorly to interferon a-2a therapy. However, the response 
was significantly better in patients with elevated ALT 
levels[13]. In HBeAg-negative CHB patients treated with 
Peginterferon a-2a, with or without lamivudine, a high 
baseline ALT level was identified as a significant predictor 
of  virological response at weeks 24 post-treatment[8].
Besides high baseline serum ALT level, we also found 
that higher TT4 level and lower baseline serum TSH level 
were associated with better outcome of  Peginterferon 
a-2b therapy in HBeAg-positive CHB patients. 
Although no study exploring the predictive value of  
virological response for baseline serum TT4 in chronic 
hepatitis B patients has been reported, several studies 
have demonstrated a reciprocal relationship between the 
endocrine and immune systems. Recently a study showed 
that triiodothyronine and thyroxin concentrations were 
Characteristic All patients (n  = 21) Responders (n  = 10) Non-responders (n  = 11) P  value
Median age, range (yr)      25 (20-39)         25 (20-38)              25 (20-39)   0.749
Gender, male (%)      81        70               91   0.311
HBV genotype (%B, C)      24, 76        10, 90              36, 64   0.311
Median HBV DNA levels, range [log (IU/mL)]     8.2 (7.5-8.7)        7.7 (7.2-8.4)             8.4 (8.1-8.8)   0.090
Median ALT level, range (IU/L)    147 (123-201)       184 (146-247)            124 (112-148)   0.011a
Median AST level, range (IU/L)      65 (51-97)         90 (57-132)              64 (45-73)   0.072
Median TSH levels, range (mIU/L)   2.06 (1.41-3.10)      1.82 (1.14-2.08)           2.55 (1.68-4.11)   0.035c
Median TT3 levels, range (nmol/L)   2.22 (2.04-3.03)      2.85 (2.02-3.85)           2.20 (2.02-2.54)   0.305
Median TT4 levels, range (nmol/L) 111.4 (96.8-140.6)    132.7 (109.0-168.5)         107.8 (88.4-117.3)   0.037e
Table 1  Baseline characteristics of patients 
Data are expressed as the median (IQR) and as percentages. HBV: Hepatitis B virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TSH: 
Thyroid-stimulating hormone. aP < 0.05 differences of baseline serum ALT level between responders and non-responders; cP < 0.05 differences of baseline se-
rum TSH level between responders and non-responders; eP < 0.05 differences of baseline serum TT4 level between responders and non-responders.
Parameters Responders Non-responders Predictive 
value (%)
ALT ≥ 140 9 3  PPV = 75
ALT < 140 1 8 NPV = 89
TSH < 2.4 9 3  PPV = 75
TSH ≥ 2.4 1 8 NPV = 89
TT4 ≥ 120 6 2  PPV = 75
TT4 < 120 3 9 NPV = 75
ALT ≥ 140, TT4 ≥ 120 6 1  PPV = 86
ALT < 140, TT4 < 120 1 7 NPV = 88
ALT ≥ 140, TSH < 2.4 8 1  PPV = 89
ALT < 140, TSH ≥ 2.4 0 6   NPV = 100
TT4 ≥ 120, TSH < 2.4 5 1  PPV = 83
TT4 < 120, TSH ≥ 2.4 0 7   NPV = 100
Table 2  Predictive value of single and combined baseline factors
Data are expressed as numbers of instances. PPV: Positive predictive 
values; NPV: Negative predictive values.
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positively associated with markers of  inflammation, 
natural killer-like T cells,  activated monocytes derived 
interleukin-6 (IL-6), higher expression of  IL-2 receptor 
on CD3+ T-lymphocytes, and percentage expression of  
memory T-lymphocytes, memory T-helper lymphocytes 
and memory T-cytotoxic lymphocytes within normal 
physiological ranges[20]. This is supported by previous 
findings that thyroid hormone was involved in primary 
and secondary lymphopoiesis, and blastogenic responses 
to T and B cell mitogens were also enhanced following 
thyroxin administration[21,22]. Other studies showed that 
thyroxin did not induce resting T lymphocyte proliferation 
but increased mitogen ConA-induced stimulation after 
three days of  culture, in a dose-dependent manner. 
Thyroxin substitutive treatment restored the euthyroid 
status and reversed the impairment of  T-cell activation 
induced by chronic stress in mice[23,24]. Interestingly, 
the age-dependent immunological deterioration in 
old mice could be recovered by thyroxin treatment[25]. 
These results indicated that thyroxin could enhance the 
immune response. Thus, this may be the reason why the 
responders who had higher baseline TT4 level achieved 
virological response more easily during Peginterferon 
a-2b therapy in our study.
Another major finding was the lower baseline TSH 
level of  responders was also associated with higher 
virological response rate. This could be caused by 
the negative feedback mechanism due to their higher 
baseline serum TT4 level. 
In conclusion, the identification and application 
of  baseline factors to predict virological response of  
chronic hepatitis B patients before antiviral therapy is 
important. Using this method, we can identify patients 
who will most likely benefit from Peginterferon a-2b 
therapy before treatment. However, because of  the 
small cohort of  patients enrolled in our study, large-scale 
studies are needed to further confirm our results and to 
identify simpler and more appropriate factors that have 




Early prediction of virological response for chronic hepatitis B patients treated 
with antiviral drugs is important. Some factors such as HBsAg and HBeAg 
reduction have been found to have high predictive values of sustained 
virological response in chronic hepatitis B patients treated with Peginterferon 
a-2a. However, the predictive values of other factors, especially the baseline 
factors for virological response to Peginterferon a-2b therapy, are not clear.
Research frontiers
Many studies have shown that an elevated serum alanine aminotransferase 
(ALT) level was associated with virological response and HBeAg seroconversion 
in CHB patients. Recent studies showed a reciprocal relationship between the 
endocrine and immune system. In this study, the authors showed that baseline 
serum ALT, thyroid-stimulating hormone (TSH), and total thyroxin (TT4) levels, 
and especially combinations of these factors, have high predictive values of 
virological response to Peginterferon a-2b in HBeAg-positive CHB patients.
Innovations and breakthroughs
The present study demonstrated that baseline serum ALT, TSH, and TT4 levels, 
and especially combinations of these factors, have high predictive values of 
virological response to Peginterferon a-2b in HBeAg-positive chronic hepatitis 
B (CHB) patients before treatment.
Applications
This study might represent a future strategy for identifying chronic hepatitis B 
patients who will most likely benefit from Peginterferon a-2b therapy before 
treatment.
Terminology
ALT is an enzyme that is normally present in liver and heart cells. ALT is 
released into blood when the liver or heart is damaged. TSH is a peptide 
hormone synthesized and secreted by thyrotrope cells in the anterior pituitary 
gland which regulates the endocrine function of the thyroid gland. Thyroxin 
(T4) is a form of thyroid hormone which is the major hormone secreted by the 
follicular cells of the thyroid gland.
Peer review
This study is of interest as it describes the relationship of virological response 
to Peginterferon a-2b therapy and serum parameters at pretreatment, although 
this was obtained in a very small cohort of patients.
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